Detail akcie Evotec Depository Receipt online

Business Summary: Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Evotec SE (ADR) revenues decreased 1% to EUR788.4M. Net loss applicable to common stockholders decreased 47% to EUR103.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Reorganization costs decrease of 99% to EUR633K (expense), G/L on Invest HFS, Maturity & Trading decrease of 98% to EUR677K (expense).